
NASCENT
BIOTECH, INC.
NBIO:OTCQB
Corporate Overview
Non-Confidential Information
October 2019
NASCENT

Safe Harbor for Forward-Looking Statements

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Nascent Biotech, Inc. (“NBI”) or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this presentation, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein, and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage companies. Any use of this information for any purpose other than in connection with the consideration of an investment in Nascent Biotech, Inc. (“NBI”) may subject the user to criminal and civil liability. This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by NBI.

Contents

NASCENT BIOTECH, INC.

Overview -- Nascent Biotech and Pritumumab

Founded

- A Nevada public company (NBIO:OTCQB); headquartered in San Diego, CA
- Formed in 2014 to continue development of Pritumumab, a fully human IgG monoclonal antibody, to treat epithelial cancers.
  - Founder: Mark Glassy, Ph.D. (UCSD; Scripps Clinic and Research Foundation)

Technology

- Original antibody developed at UCSD

Stage

- IND Approved in 2019
- Initiate Phase 1 trials in Brain Cancer in early 2020
- Complete IND for Pancreatic Cancer (1H, 2020)
- Initiate clinical trials in Pancreatic Cancer in 2H, 2020

Focus

- Initiate clinical trial programs for Pritumumab
- Evaluate in-licensing opportunities to augment pipeline
  - Immune-stimulating, cancer vaccines, antibody platforms

IP

- Worldwide rights for Pritumumab
- License agreement with Zhejiang Hisun for China market (Brain Cancer only)
  - $16M total plus 10% royalty for 20 years
  - $3M upfront payment;
  - Future milestone payments
- Orphan Drug Designation granted for Brain Cancer and Pancreatic Cancer

Financing

- Raised $7M to date
- Seeking $11.55M - Fund initiation of clinical trials in Brain Cancer / Pancreatic Cancer

NASCENT BIOTECH, INC.

Nascent Biotech Development Pipeline

Patient-derived Monoclonal Antibody



PROGRAM	NONCLIN R&D	PHASE 1	PHASE 2	PARTNER
Brain cancer		*U.S. (2020)*		NASCENT BIOTECH, INC. / HISUN 海正药业 China
*Pancreatic cancer**	*U.S.*			NASCENT BIOTECH, INC.
*Gynecologic**	*U.S.*			NASCENT BIOTECH, INC.

** Market Expansion to pancreatic and gynecologic cancers in 2021*

NASCENT BIOTECH, INC.

Brain Cancer and Pancreatic Cancer represent a significant Unmet Need

Brain Cancer

- 1-year & 5-year survival rates for current 1st-line therapeutic strategies (surgery, TEMODAR®) are:
  - 60% and 35%, respectively, for all brain cancers
  - 36% and 5%, respectively, for glioblastomas
    - *SEER Registry Data (June 2016)*
- ~23,000 new cases in the U.S. each year
  - *GLOBOCAN/WHO (2012)*
- Brain metastases will occur in a significant number of all cancer patients (180,000 in the U.S.)
  - *National Cancer Institute (February 25, 2015)*

Pancreatic Cancer

- ~36,000 new cases in the U.S. each year
- Similar number of deaths in the U.S. each year
- 1-year and 5-year survival rates are 20% and 7%, respectively, for all pancreatic cancers

Pritumumab Targets Cancer-Associated Vimentin



NASCENT BIOTECH, INC.



Non-Clinical Development of Pritumumab in U.S.

Including IND-Enabling Studies & IND Submission

NASCENT BIOTECH, INC.

Summary Of Non-Clinical Development in the U.S.

- ✓ Fully human recombinant monoclonal antibody (mAb) produced in the novel CHO expression system at Catalent
- ✓ Exploratory and IND-enabling studies completed in U.S.
  - Revalidation: mAb specifically recognizes cell surface Vimentin
  - Binding to the recombinant protein & flow cytometry
  - Immuno-histochemistry staining of normal and tumor tissues (human, monkey)
  - Anti-tumor activity in mouse models
  - Excellent safety and pharmacokinetics
- ✓ IND approved with first registration batch of Pritumumab
- ✓ Phase 1 trial to begin Q1, 2020
- ✓ Orphan Drug Designation received from FDA for treatment of gliomas (2015) and pancreatic cancer (2016)

Hybridoma-derived Pritumumab Compared to Pritumumab produced in Chinese Hamster Ovary (CHO) Cell Line

The original Pritumumab studied previously was Hybridoma-derived. Nascent has reformulated Pritumumab to be expressed in CHO cells.

The binding profiles of the human hybridoma-derived mAb, and the recombinant mAb expressed in CHO cells, were found to be similar.

- ✓ ***This has been confirmed in multiple biological assays***

Comparison	Human Hybridoma-derived mAb	GPEx CHO Pritumumab
FACS binding	Yes	Yes
Tissue IHC	Yes	Yes
Amino acid sequence 100% match	Yes	Yes
Fc portion of heavy chain match	Identical	Identical
CDR sequences match	Identical	Identical

Recombinant mAb characterized and produced in U.S. by Catalent & Nascent

NASCENT BIOTECH, INC.

Imaging Of Brain Cancer with ^{89}Zr-labeled Pritumumab

Imaging studies show preferential tumor uptake of Pritumumab



Schema for DFO chelator conjugation to PRIT and subsequent radiolabeling of antibody with Zr-89

- Dr. Pillarsetty (MSKCC) & Nascent Biotech

PET/CT slices and maximum intensity projections



Autoradiography



NASCENT BIOTECH, INC.

Imaging Of Brain Cancer with ^{89}Zr-labeled Pritumumab

Subcutaneous Tumor Model - U251 GBM Cell Line





- Dr. Pillarsetty (MSKCC) & Nascent Biotech

Representative images displaying transaxial and coronal PET slices (top) and maximum intensity projections (bottom) of a mouse bearing subcutaneous U251 xenografts at 4, 24, 48, 72 and 144 h post injection. Tumors have been highlighted in coronal slices.

NASCENT BIOTECH, INC.

Imaging Of Brain Cancer with Cy5.5-labeled Pritumumab

Pritumumab accumulates at the tumor site and is retained for a sustained period

C6 Orthotopic Brain Tumors



- Hisun Pharma, University of Peking & Nascent Biotech

U87 Orthotopic Brain Tumors



NASCENT BIOTECH, INC.

Capital Investment - Timeline and Budget

-- Initiation of Brain Cancer Phase 1 Trial
-- File IND for Pancreatic Cancer
-- Fund Ongoing Company Operations through 2021

NASCENT BIOTECH, INC.

$11.55M Capital Investment

Initiate Clinical Trials, Achieve Near-term Milestones, Finance Operations



NASCENT BIOTECH, INC.

Nascent Biotech Inc. - Investment Highlights

A Growing Biotechnology Company Developing First-in-class Monoclonal Antibody Therapies to Treat Orphan Oncology Indications Having Significant Unmet Need

Derisked Opportunity: Well-differentiated agent with promising anti-tumor activity in patients	**Pritumumab: a fully Human Monoclonal Antibody** – IND-approved in U.S. for patients with brain cancer – Phase 1 IRB approval; Enrollment to commence April 2020 – *Pritumumab* has been granted Orphan Drug Designation by the FDA for treatment of Gliomas (brain cancers) and Pancreatic Cancer – Orphan or biologic drugs are approved at higher rates.
Multiple Corporate Partnership Opportunities	**License Agreement with Zhejiang Hisun for China Market:** – $16M plus 10% royalty for 20 years – $3M upfront payment – Future Milestone Payments – Potential to combine with other targeted agents or immunotherapies
Exit Opportunities	– Public listing on Nasdaq in 2020 – $1B+ potential commercial opportunity in lead indications

NASCENT BIOTECH, INC.

Leadership Team Focused On Execution

Prior Experience

Sean Carrick
President, Chief Executive Officer

Brandon Price, Ph.D.
Executive VP, Business Development

Lowell Holden
Chief Financial Officer

Douglas Karas
Board of Directors

Mark Glassy, Ph.D.
Founder; Chairman - Scientific Advisory Board

Sean Carrick, CEO
sean.carrick@nascentbiotech.com

Barrett S. McGrath
Corporate Development
barrett.mcgrath@nascentbiotech.com

6330 Nancy Ridge Dr
Suite 105
San Diego, CA 92121
(772) 713-0541